search
Back to results

Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity (ONCORE)

Primary Purpose

Cardiotoxicity, Cardiac Rehabilitation

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Cardiac rehabilitation
Sponsored by
Hospital Clinico Universitario de Santiago
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Cardiotoxicity focused on measuring Chemotherapy, Anthracyclines, Trastuzumab, Pertuzumab, Antibodies, Monoclonal, Humanized, Breast Cancer, Exercise therapy

Eligibility Criteria

18 Years - 69 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • First diagnosis of breast cancer at early stages (I, II, III)
  • Treatment with anthracyclines and / or anti-HER-2 antibodies (trastuzumab and / or pertuzumab)
  • Possibility of completing a cardiac rehabilitation program (centre-based or telematic) and programmed visits.
  • Providing written informed consent.

Exclusion Criteria:

  • Patients with previous history of heart disease or heart failure.
  • Left ventricular dysfunction (left ventricular ejection fraction <53%) at baseline.
  • Metastatic disease.
  • Patients carrying an implantable cardioverter defibrillator.
  • Patients with physical or mental limitation to carry out an exercise program.

Sites / Locations

  • Hospital Clínico Universitario de Santiago

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Cardiac Rehabilitation

Conventional management

Arm Description

Patients enrolled in the integrated exercise-based cardiac rehabilitation program (centre-based or telematic)

Patients with conventional management and physical activity recommendation

Outcomes

Primary Outcome Measures

Change in left ventricular systolic function quantified by left ventricular ejection fraction and global longitudinal strain by transthoracic echocardiography
Fall of 10 absolute percentage points of left ventricular ejection fraction with final value below 53% or global longitudinal strain fall >15% with respect to baseline

Secondary Outcome Measures

Change in health-related quality of life assessed by the Functional Assessment of Cancer Therapy - Breast plus Arm Morbidity (FACT-B+4) questionnaire
Score achieved in the Functional Assessment of Cancer Therapy - Breast plus Arm Morbidity (FACT-B+4) questionnaire, a specific validated scale to assess quality of life of women with breast cancer. It comprises 27 items within 5 areas of assessment: physical well-being (7 items), social and family environment (7 items), emotional well-being (7 items), functional well-being (6 items) and worries related to the diagnosis and treatment of the disease (9 items). Each item is scored by means of a Likert scale from 0 to 5, with higher scores representing better results. The total score is obtained by adding the scores for each item, and ranges from a minimum of 0 (worst posible result) to a maximum of 146 (best possible result).
Change in tolerance to chemotherapy: number of participants with significant cardiovascular and non-cardiovascular adverse effects throughout the study
Significant cardiovascular and non-cardiovascular adverse effects during treatment, threatening life, requiring admission, prolonging hospitalization, being clinically relevant or causing chemotherapy interruptions
Change in global functional capacity assessed by conventional ergometry, cardiopulmonary exercise testing (CPET) or the 6-minute walking test (6MWT).
Change in functional capacity assessed by conventional ergometry, cardiopulmonary exercise test or the 6-minute walking test (6MWT) (metabolic equivalents: METs or peak oxygen consumption: VO2) * . *Due to COVID-19 pandemic, participants' assessment with CPET had to be stopped for safety concerns. In such cases, functional capacity was estimated from the maximum work rate in the 6-minute walking test (6MWT). This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes, which is well correlated with VO2. The 6MWT has been proved to be valid and reliable for functional capacity assessment in the study population.
Change in localized lower limb functional capacity assessed by number of repetitions performed within 30 seconds in the sit-to-stand test
Number of repetitions in the sit-to-stand test within 30 seconds
Change in shoulder functional capacity assessed by range of degrees in shoulder movement by goniometry
Range of degrees in shoulder movement measured by goniometry
Change in upper limb strength measured by dynamometry (kg)
Kilograms by dynamometry of right and left upper limbs
Change in shoulder pain and disability assessed by the SPADI (shoulder pain and disability index (SPADI) questionnaire
Score achieved in the SPADI (shoulder pain and disability index) questionnaire. The pain dimension consists of five questions regarding the severity of an individual's pain, functional activities are assessed with eight questions. Each question may be scored from 0 to 10. Verbal anchors for the pain dimension are 'no pain at all' (0) and 'worst pain imaginable' (10) ,and those for the functional activities are 'no difficulty' (0) and 'so difficult it required help' (10). The scores from both dimensions are averaged to produce a total score ranging from 0 (best) to 100 (worst).
Change in cardiovascular risk profile as assessed by the presence or absence of classic cardiovascular risk factors
Dyslipidemia, Diabetes mellitus, Arterial Hypertension, Smoking status
Change in anthropometric parameters: height in cm
Height measured in cm
Change in anthropometric parameters: weight in kg
Weight measured in kg
Change in anthropometric parameters: body mass index (BMI) in kg/m^2
Weight and height will be combined to report BMI in kg/m^2
Change in anthropometric parameters: abdominal circumference in cm
Abdominal perimeter measured with a tape measure in cm
Change in resting heart rate measured by pulse oximetry (beats per min)
Resting heart rate by pulse oximetry (beats per min)
Change in resting blood pressure (mmHg) measured by sphygmomanometer
Resting blood pressure by sphyngomanometer in mmHg
Change in biomarkers NT-ProBNP
Value of NT-ProBNP(pg/mL) in blood tests
Change in biomarkers: troponin
Value of troponin I (ng/mL) in blood tests
Change in biomarkers: haemoglobin
Value of haemoglobin (g/dL) in blood tests
Change in dietary pattern as assessed by the PREDIMED (PREvención con DIeta MEDiterránea) questionnaire
Validated questionnaire to assess adherence to Mediterranean diet, including 14 questions regarding dietary habits, rated with 0 or +1 points. Global score is calculated by summing points and ranges from 0 to 14, with higher score representing higher adherence.
Change in the score for depression assessed by Zigmond and Snaith questionnaire to rate anxiety and depression
Score achieved in the depression subscale of the Zigmond and Snaith test for anxiety or depression, a self-applied questionnaire. Depression scale includes 7 items each, scored on Likert scale from 0 to 3. Global score ranges from 0 to 21, with higher scores representing greater depression. The authors suggest that scores higher than eleven would indicate "case" and more than eight would be considered "probable case" (Zigmond and Snaith, 1983).
Change in the score for anxiety assessed by the Zigmond and Snaith questionnaire to rate depression and anxiety
Score achieved in the anxiety subscale of the Zigmond and Snaith test for anxiety or depression, a self-applied questionnaire. Anxiety scale includes 7 items each, scored on Likert scale from 0 to 3. Global score ranges from 0 to 21, with higher scores representing greater anxiety. The authors suggest that scores higher than eleven would indicate "case" and more than eight would be considered "probable case" (Zigmond and Snaith, 1983).
Change in physical activity (minutes of dedicated physical activity)
Minutes of In- and out-of-hospital dedicated physical activity
Change in physical activity assessed by the score in the Godin Leisure Test Exercise Questionnaire (GLTEQ)
Score achieved in the Godin Leisure Test Exercise Questionnaire (GLTEQ) for quantification of physical activity. Activities are classified into three subgroups: "strenuous," "moderate," and "light." The scores corresponding to the energy expenditure (metabolic equivalent (MET)) are obtained by multiplying activities performed for more than 15 min in a week with their coefficients. The numbers represent the MET intensity values (strenuous/ exhausting exercises: 9 METs, moderate exercises: 5 METs, and light exercises: 3 METs).The increasing scores are associated with the increasing number of exercise behaviors, providing references about the contribution of physical activity to health: the activity score of 24 units and more as active (substantial benefits); the activity score of 14-23 units as moderately active (some benefits); and the activity score of 13 units and less as inactive (less substantial or low benefits).
Change in lymphedema assessed by perimeter of the upper limb by cirtometry (cm), stage and grade
Perimeter of the upper limb by cirtometry (cm), stage and grade as defined by the Spanish Society of Rehabilitation and Physical Medicine

Full Information

First Posted
February 21, 2019
Last Updated
May 11, 2023
Sponsor
Hospital Clinico Universitario de Santiago
Collaborators
Instituto de Salud Carlos III
search

1. Study Identification

Unique Protocol Identification Number
NCT03964142
Brief Title
Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity
Acronym
ONCORE
Official Title
Randomized Controlled Trial on Comprehensive Exercise-based Cardiac Rehabilitation Programs for the Prevention of Anthracyclines and/or Anti-HER2 Antibodies-induced Cardiotoxicity in Breast Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
August 1, 2018 (Actual)
Primary Completion Date
March 30, 2022 (Actual)
Study Completion Date
January 1, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hospital Clinico Universitario de Santiago
Collaborators
Instituto de Salud Carlos III

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This project aims to determine whether a comprehensive cardiac rehabilitation program including supervised exercise training is able to prevent cardiotoxicity during treatment with anthracyclines and / or anti-HER-2 antibodies in women with breast cancer. Participants will be randomly allocated to cardiac rehabilitation (intervention group) or conventional management with physical exercise recommendation (control group).
Detailed Description
Cardiovascular toxicity caused by chemotherapy is the leading cause of death in patients who survive cancer. Physical exercise during chemotherapy has shown to improve quality of life and decrease the risk of death. The objective of this project is to determine whether an intervention through a comprehensive cardiac rehabilitation program including supervised physical exercise is able to prevent anthracyclines and / or anti-HER-2 antibodies-induced cardiotoxicity in women with breast cancer. For this purpose, the investigators intend to conduct a randomized controlled study including female patients managed under the same cardiotoxicity prevention protocol (clinical, laboratory and echocardiographic follow-up assessment). Patients will be randomized to a non-pharmacological intervention (participation in a multidisciplinary cardiac rehabilitation program with supervised exercise training) or control (conventional management and physical activity recommendation)*. The investigators hypothesize that a cardiac rehabilitation program may limit chemotherapy-induced cardiotoxicity in women with breast cancer, improve cardiac remodeling assessed by echocardiography and enhance their global cardiovascular risk profile to a greater extent, compared to control group. * OF NOTE: Due to the COVID-19 pandemics, several modifications to the original protocol were introduced for safety reasons or motivated by the health situation, namely: Intervention: Change from centre-based to telematic supervised exercise training sessions provided within the cardiac rehabilitation program (intervention group) Secondary outcome 4: Change in functional capacity assessed by conventional ergometry or cardiopulmonary exercise test OR the 6-minute walking test (metabolic equivalents: METs or peak oxygen consumption: VO2) Recruiting centres: One centre (Hospital Universitari Vall d'Hebron) withdrew from the study due to the impossibility of assuming its execution.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiotoxicity, Cardiac Rehabilitation
Keywords
Chemotherapy, Anthracyclines, Trastuzumab, Pertuzumab, Antibodies, Monoclonal, Humanized, Breast Cancer, Exercise therapy

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
122 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cardiac Rehabilitation
Arm Type
Experimental
Arm Description
Patients enrolled in the integrated exercise-based cardiac rehabilitation program (centre-based or telematic)
Arm Title
Conventional management
Arm Type
No Intervention
Arm Description
Patients with conventional management and physical activity recommendation
Intervention Type
Other
Intervention Name(s)
Cardiac rehabilitation
Intervention Description
Integrated cardiac rehabilitation program that includes supervised exercise training*. * Due to the COVID-19 pandemic, supervised physical exercise training had to be conducted telematically (through live guided training sessions conducted online, with the same design, frequency, and dosage of exercise).
Primary Outcome Measure Information:
Title
Change in left ventricular systolic function quantified by left ventricular ejection fraction and global longitudinal strain by transthoracic echocardiography
Description
Fall of 10 absolute percentage points of left ventricular ejection fraction with final value below 53% or global longitudinal strain fall >15% with respect to baseline
Time Frame
Baseline to every 3 months through study completion, at the end of the study at an average of 18 months, and every year after study completion up to a maximum of 5 years
Secondary Outcome Measure Information:
Title
Change in health-related quality of life assessed by the Functional Assessment of Cancer Therapy - Breast plus Arm Morbidity (FACT-B+4) questionnaire
Description
Score achieved in the Functional Assessment of Cancer Therapy - Breast plus Arm Morbidity (FACT-B+4) questionnaire, a specific validated scale to assess quality of life of women with breast cancer. It comprises 27 items within 5 areas of assessment: physical well-being (7 items), social and family environment (7 items), emotional well-being (7 items), functional well-being (6 items) and worries related to the diagnosis and treatment of the disease (9 items). Each item is scored by means of a Likert scale from 0 to 5, with higher scores representing better results. The total score is obtained by adding the scores for each item, and ranges from a minimum of 0 (worst posible result) to a maximum of 146 (best possible result).
Time Frame
Baseline and at the end of the study at an average of 18 months
Title
Change in tolerance to chemotherapy: number of participants with significant cardiovascular and non-cardiovascular adverse effects throughout the study
Description
Significant cardiovascular and non-cardiovascular adverse effects during treatment, threatening life, requiring admission, prolonging hospitalization, being clinically relevant or causing chemotherapy interruptions
Time Frame
Every 3 months during study completion and at the end of the study at an average of 18 months
Title
Change in global functional capacity assessed by conventional ergometry, cardiopulmonary exercise testing (CPET) or the 6-minute walking test (6MWT).
Description
Change in functional capacity assessed by conventional ergometry, cardiopulmonary exercise test or the 6-minute walking test (6MWT) (metabolic equivalents: METs or peak oxygen consumption: VO2) * . *Due to COVID-19 pandemic, participants' assessment with CPET had to be stopped for safety concerns. In such cases, functional capacity was estimated from the maximum work rate in the 6-minute walking test (6MWT). This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes, which is well correlated with VO2. The 6MWT has been proved to be valid and reliable for functional capacity assessment in the study population.
Time Frame
Baseline and at the end of the study at an average of 18 months
Title
Change in localized lower limb functional capacity assessed by number of repetitions performed within 30 seconds in the sit-to-stand test
Description
Number of repetitions in the sit-to-stand test within 30 seconds
Time Frame
Baseline and at the end of the study at an average of 18 months
Title
Change in shoulder functional capacity assessed by range of degrees in shoulder movement by goniometry
Description
Range of degrees in shoulder movement measured by goniometry
Time Frame
Baseline and at the end of the study at an average of 18 months
Title
Change in upper limb strength measured by dynamometry (kg)
Description
Kilograms by dynamometry of right and left upper limbs
Time Frame
Baseline and at the end of the study at an average of 18 months
Title
Change in shoulder pain and disability assessed by the SPADI (shoulder pain and disability index (SPADI) questionnaire
Description
Score achieved in the SPADI (shoulder pain and disability index) questionnaire. The pain dimension consists of five questions regarding the severity of an individual's pain, functional activities are assessed with eight questions. Each question may be scored from 0 to 10. Verbal anchors for the pain dimension are 'no pain at all' (0) and 'worst pain imaginable' (10) ,and those for the functional activities are 'no difficulty' (0) and 'so difficult it required help' (10). The scores from both dimensions are averaged to produce a total score ranging from 0 (best) to 100 (worst).
Time Frame
Baseline and at the end of the study at an average of 18 months
Title
Change in cardiovascular risk profile as assessed by the presence or absence of classic cardiovascular risk factors
Description
Dyslipidemia, Diabetes mellitus, Arterial Hypertension, Smoking status
Time Frame
Baseline and at the end of the study at an average of 18 months
Title
Change in anthropometric parameters: height in cm
Description
Height measured in cm
Time Frame
Baseline and at the end of the study at an average of 18 months
Title
Change in anthropometric parameters: weight in kg
Description
Weight measured in kg
Time Frame
Baseline and at the end of the study at an average of 18 months
Title
Change in anthropometric parameters: body mass index (BMI) in kg/m^2
Description
Weight and height will be combined to report BMI in kg/m^2
Time Frame
Baseline and at the end of the study at an average of 18 months
Title
Change in anthropometric parameters: abdominal circumference in cm
Description
Abdominal perimeter measured with a tape measure in cm
Time Frame
Baseline and at the end of the study at an average of 18 months
Title
Change in resting heart rate measured by pulse oximetry (beats per min)
Description
Resting heart rate by pulse oximetry (beats per min)
Time Frame
Baseline and at the end of the study at an average of 18 months
Title
Change in resting blood pressure (mmHg) measured by sphygmomanometer
Description
Resting blood pressure by sphyngomanometer in mmHg
Time Frame
Baseline and at the end of the study at an average of 18 months
Title
Change in biomarkers NT-ProBNP
Description
Value of NT-ProBNP(pg/mL) in blood tests
Time Frame
Baseline and at the end of the study at an average of 18 months
Title
Change in biomarkers: troponin
Description
Value of troponin I (ng/mL) in blood tests
Time Frame
Baseline and at the end of the study at an average of 18 months
Title
Change in biomarkers: haemoglobin
Description
Value of haemoglobin (g/dL) in blood tests
Time Frame
Baseline and at the end of the study at an average of 18 months
Title
Change in dietary pattern as assessed by the PREDIMED (PREvención con DIeta MEDiterránea) questionnaire
Description
Validated questionnaire to assess adherence to Mediterranean diet, including 14 questions regarding dietary habits, rated with 0 or +1 points. Global score is calculated by summing points and ranges from 0 to 14, with higher score representing higher adherence.
Time Frame
Baseline and at the end of the study at an average of 18 months
Title
Change in the score for depression assessed by Zigmond and Snaith questionnaire to rate anxiety and depression
Description
Score achieved in the depression subscale of the Zigmond and Snaith test for anxiety or depression, a self-applied questionnaire. Depression scale includes 7 items each, scored on Likert scale from 0 to 3. Global score ranges from 0 to 21, with higher scores representing greater depression. The authors suggest that scores higher than eleven would indicate "case" and more than eight would be considered "probable case" (Zigmond and Snaith, 1983).
Time Frame
Baseline and at study completion at an average of 18 months, plus at the end of training (at an average of 12 to 15 months) in the intervention group
Title
Change in the score for anxiety assessed by the Zigmond and Snaith questionnaire to rate depression and anxiety
Description
Score achieved in the anxiety subscale of the Zigmond and Snaith test for anxiety or depression, a self-applied questionnaire. Anxiety scale includes 7 items each, scored on Likert scale from 0 to 3. Global score ranges from 0 to 21, with higher scores representing greater anxiety. The authors suggest that scores higher than eleven would indicate "case" and more than eight would be considered "probable case" (Zigmond and Snaith, 1983).
Time Frame
Baseline and at study completion, plus at the end of training (at an average of 12 to 15 months) in the intervention group
Title
Change in physical activity (minutes of dedicated physical activity)
Description
Minutes of In- and out-of-hospital dedicated physical activity
Time Frame
Baseline and at study completion at an average of 18 months
Title
Change in physical activity assessed by the score in the Godin Leisure Test Exercise Questionnaire (GLTEQ)
Description
Score achieved in the Godin Leisure Test Exercise Questionnaire (GLTEQ) for quantification of physical activity. Activities are classified into three subgroups: "strenuous," "moderate," and "light." The scores corresponding to the energy expenditure (metabolic equivalent (MET)) are obtained by multiplying activities performed for more than 15 min in a week with their coefficients. The numbers represent the MET intensity values (strenuous/ exhausting exercises: 9 METs, moderate exercises: 5 METs, and light exercises: 3 METs).The increasing scores are associated with the increasing number of exercise behaviors, providing references about the contribution of physical activity to health: the activity score of 24 units and more as active (substantial benefits); the activity score of 14-23 units as moderately active (some benefits); and the activity score of 13 units and less as inactive (less substantial or low benefits).
Time Frame
Baseline and at study completion at an average of 18 months
Title
Change in lymphedema assessed by perimeter of the upper limb by cirtometry (cm), stage and grade
Description
Perimeter of the upper limb by cirtometry (cm), stage and grade as defined by the Spanish Society of Rehabilitation and Physical Medicine
Time Frame
Baseline after surgery and 2-4 weeks after the end of chemotherapy (at an average of 12 to 15 months)
Other Pre-specified Outcome Measures:
Title
Adherence and compliance to cardiac rehabilitation program (intervention group) assessed by number of training sessions attended/ number of sessions planned
Description
Number of training sessions attended / number of sessions planned
Time Frame
At the end of the cardiac rehabilitation program at an average of 12 to 15 months
Title
Security of the cardiac rehabilitation program assessed by number of adverse events during training (intervention group)
Description
Adverse events during training
Time Frame
At the end of the cardiac rehabilitation program at an average of 12 to 15 months
Title
Changes in expectations regarding the cardiac rehabilitation program assessed by a questionnaire (intervention group)
Description
Program-related expectations at baseline and at the end of the program' are collected through an open question "What do you expect to achieve by participating in the program?" Responses regarding expectations will be categorized by the evaluator within the following areas: psychological sphere and/or social sphere and/or physical sphere. Global expectations of benefit are scored from 0 (no benefit) to 10 (highest benefit).
Time Frame
Baseline and at the end of the cardiac rehabilitation program at an average of 12 to 15 months
Title
Satisfaction with the cardiac rehabilitation program assessed by a questionnaire (intervention group)
Description
Satisfaction at the end of the program is assessed by a questionnaire including 9 questions concerning comfort with training sessions, training spaces and development of the program, which are scored from 0 (worse posible result) to 10 (best posible result). Total score is calculated by adding for each question, and ranges from 0 to 90. * Due to the introduction of telematic exercise training during COVID-19 pandemic, questions were slightly modified to include assessment of satisfaction with this training modality.
Time Frame
At the end of the cardiac rehabilitation program at an average of 12 to 15 months

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
69 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: First diagnosis of breast cancer at early stages (I, II, III) Treatment with anthracyclines and / or anti-HER-2 antibodies (trastuzumab and / or pertuzumab) Possibility of completing a cardiac rehabilitation program (centre-based or telematic) and programmed visits. Providing written informed consent. Exclusion Criteria: Patients with previous history of heart disease or heart failure. Left ventricular dysfunction (left ventricular ejection fraction <53%) at baseline. Metastatic disease. Patients carrying an implantable cardioverter defibrillator. Patients with physical or mental limitation to carry out an exercise program.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amparo Martínez Monzonís, MD, PhD
Organizational Affiliation
Cardiology Department, Hospital Clínico Universitario de Santiago, CIBER-CV
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Carlos Peña Gil, MD, PhD
Organizational Affiliation
Cardiology Department, Hospital Clínico Universitario de Santiago, CIBER-CV
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
José Ramón González Juanatey, MD, PhD
Organizational Affiliation
Cardiology Department, Hospital Clínico Universitario de Santiago, CIBER-CV
Official's Role
Study Director
Facility Information:
Facility Name
Hospital Clínico Universitario de Santiago
City
Santiago de Compostela
State/Province
A Coruña
ZIP/Postal Code
15706
Country
Spain

12. IPD Sharing Statement

Citations:
PubMed Identifier
35819522
Citation
Diaz-Balboa E, Gonzalez-Salvado V, Rodriguez-Romero B, Martinez-Monzonis A, Pedreira-Perez M, Cuesta-Vargas AI, Lopez-Lopez R, Gonzalez-Juanatey JR, Pena-Gil C. Thirty-second sit-to-stand test as an alternative for estimating peak oxygen uptake and 6-min walking distance in women with breast cancer: a cross-sectional study. Support Care Cancer. 2022 Oct;30(10):8251-8260. doi: 10.1007/s00520-022-07268-z. Epub 2022 Jul 11.
Results Reference
derived
PubMed Identifier
33827450
Citation
Diaz-Balboa E, Gonzalez-Salvado V, Rodriguez-Romero B, Martinez-Monzonis A, Pedreira-Perez M, Palacios-Ozores P, Lopez-Lopez R, Pena-Gil C, Gonzalez-Juanatey JR. A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol. BMC Cardiovasc Disord. 2021 Apr 7;21(1):165. doi: 10.1186/s12872-021-01970-2.
Results Reference
derived

Learn more about this trial

Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity

We'll reach out to this number within 24 hrs